Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
December 2, 2024
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
November 27, 2024
Novocure to Participate in Upcoming Investor Conferences
November 21, 2024
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
November 21, 2024
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
October 30, 2024
Novocure Appoints Christoph Brackmann as Chief Financial Officer
October 30, 2024
Novocure Reports Third Quarter 2024 Financial Results
October 15, 2024
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
October 1, 2024
Novocure to Report Third Quarter 2024 Financial Results
September 9, 2024
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
September 3, 2024
Novocure Announces Planned CEO Transition
August 28, 2024
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
August 14, 2024
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
July 25, 2024
Novocure Reports Second Quarter 2024 Financial Results
July 1, 2024
Novocure to Report Second Quarter 2024 Financial Results
June 3, 2024
METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
May 23, 2024
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany
May 2, 2024
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
May 2, 2024
Novocure Reports First Quarter 2024 Financial Results
April 24, 2024
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
April 5, 2024
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
April 1, 2024
Novocure to Report First Quarter 2024 Financial Results
March 27, 2024
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
March 11, 2024
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
February 22, 2024
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
January 18, 2024
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
January 9, 2024
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
January 8, 2024
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
January 4, 2024
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer